Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

Business has been booming for the company, a multispecialty telehealth platform, with rapid growth in its weight loss offering, including compounded GLP-1 injection products. Hims & Hers expects ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

The guidance for FY 2025 includes revenue in the range of $2.3 billion to $2.4 billion vs the Street's estimate of $2.1 billion. Let's dive deep into this guidance. Hims & Hers projects 2025 GLP-1 ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced the resolution of the shortage of GLP-1 (semaglutide ...

Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

The U.S. District Court for the Northern District of Texas just ruled in a lawsuit related to GLP-1 weight loss drugs, and the ruling has negative implications for Hims & Hers' business. Where to ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Hims & Hers Health stock drops over 20% after the FDA removes semaglutide from the shortage list. Novo Nordisk launches a ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now soon they may be unavailable to most.